Metabolomics for clinical use and research in chronic kidney disease.
Nat. Rev. Nephrol. 13, 269-284 (2017)
Chronic kidney disease (CKD) has a high prevalence in the general population and is associated with high mortality; a need therefore exists for better biomarkers for diagnosis, monitoring of disease progression and therapy stratification. Moreover, very sensitive biomarkers are needed in drug development and clinical research to increase understanding of the efficacy and safety of potential and existing therapies. Metabolomics analyses can identify and quantify all metabolites present in a given sample, covering hundreds to thousands of metabolites. Sample preparation for metabolomics requires a very fast arrest of biochemical processes. Present key technologies for metabolomics are mass spectrometry and proton nuclear magnetic resonance spectroscopy, which require sophisticated biostatistic and bioinformatic data analyses. The use of metabolomics has been instrumental in identifying new biomarkers of CKD such as acylcarnitines, glycerolipids, dimethylarginines and metabolites of tryptophan, the citric acid cycle and the urea cycle. Biomarkers such as c-mannosyl tryptophan and pseudouridine have better performance in CKD stratification than does creatinine. Future challenges in metabolomics analyses are prospective studies and deconvolution of CKD biomarkers from those of other diseases such as metabolic syndrome, diabetes mellitus, inflammatory conditions, stress and cancer.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Typ der Hochschulschrift
Herausgeber
Schlagwörter
11-beta-hydroxysteroid Dehydrogenase Type-1; Chronic-renal-failure; Serum Cystatin-c; Chromatography-mass Spectrometry; Glomerular-filtration-rate; Oxidative Stress; Diabetic-nephropathy; Biomarker Discovery; General-population; L-carnitine
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2017
Prepublished im Jahr
HGF-Berichtsjahr
2017
ISSN (print) / ISBN
1759-5061
e-ISSN
1759-507X
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 13,
Heft: 5,
Seiten: 269-284
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Nature Publishing Group
Verlagsort
New York, NY
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
Institut(e)
Molekulare Endokrinologie und Metabolismus (MEM)
POF Topic(s)
30201 - Metabolic Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-505600-003
Förderungen
Copyright
Erfassungsdatum
2017-03-15